AstraZeneca

HUTCHMED will present updated clinical data for savolitinib, a selective MET tyrosine kinase inhibitor, at the 2025 World Conference on Lung Cancer, including results from SACHI, SAVANNAH, and Phase IIIb studies in non-small cell lung cancer patients.

Artelo Biosciences announced positive interim Phase 2 results for ART27.13, showing a 6.38% mean weight gain at 12 weeks versus 5.42% weight loss on placebo in cancer cachexia patients.

ArcaScience raised $7 million in seed funding to expand its AI platform that transforms drug benefit-risk assessments from months-long processes to seconds-long computations.

The DAPA ACT HF-TIMI 68 trial failed to show significant improvement in cardiovascular death or worsening heart failure when starting dapagliflozin during acute heart failure hospitalization, with 10.9% of treated patients versus 12.7% of placebo patients experiencing events at 60 days.

Johnson & Johnson discontinued its Phase 2 DAISY trial of nipocalimab combined with anti-TNFα therapy for rheumatoid arthritis after failing to demonstrate sufficient added benefit over monotherapy at 12 weeks.

Virginia lawmakers unanimously approved economic development packages worth over $10 million each for AstraZeneca's multibillion-dollar manufacturing plant in Albemarle County and Eli Lilly's facility in Goochland County.

Major pharmaceutical companies including AbbVie, AstraZeneca, and Merck are actively developing controlled drug release systems to enhance treatment of chronic diseases, cancer, and neurological disorders.

Tempus AI has acquired Paige, an AI company specializing in digital pathology with FDA-cleared cancer detection applications and nearly 7 million digitized pathology slides.

The Philippine Economic Zone Authority (PEZA) and AstraZeneca Pharmaceuticals Philippines have signed an agreement to create the country's first pharmaceutical innovation hub within the PEZA ecozone network.

Johnson & Johnson will invest $2 billion over 10 years to build a 160,000+ square foot manufacturing facility at Fujifilm Biotechnologies' new Holly Springs, North Carolina site.